Back to top
more

Surmodics (SRDX)

(Real Time Quote from BATS)

$35.27 USD

35.27
101,124

+0.24 (0.69%)

Updated Aug 7, 2025 01:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Surmodics (SRDX) Beats on Q3 Earnings, Revises FY22 View

by Zacks Equity Research

Product sales primarily drive Surmodics' (SRDX) third-quarter top-line growth. However, the company expects softer demand for its products and services in the second half of 2022.

Zacks Equity Research

SurModics (SRDX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

SurModics (SRDX) delivered earnings and revenue surprises of 12.82% and 2.46%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Reasons to Retain Surmodics (SRDX) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.

Zacks Equity Research

Here's Why You Should Hold on to Surmodics (SRDX) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.

Zacks Equity Research

Haemonetics (HAE) Up 28.2% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Surmodics (SRDX) Beats on Q2 Earnings, Revises FY22 View

by Zacks Equity Research

Despite solid IVD revenues, Surmodics (SRDX) reports a soft Q2 overall top line.

Zacks Equity Research

SurModics (SRDX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

SurModics (SRDX) delivered earnings and revenue surprises of 31.25% and 6.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Reasons to Add Surmodics (SRDX) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.

Zacks Equity Research

SurModics (SRDX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

SurModics (SRDX) delivered earnings and revenue surprises of 63.89% and 3.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate SurModics (SRDX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Surmodics (SRDX) Stock Loses 2.2% Despite Q4 Earnings Beat

by Zacks Equity Research

Surmodics' (SRDX) fiscal fourth-quarter results reflect benefits from segmental strength.

Zacks Equity Research

SurModics (SRDX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

SurModics (SRDX) delivered earnings and revenue surprises of 60.00% and 6.73%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate SurModics (SRDX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Surmodics' (SRDX) Latest Sublime Catheter Expands Patient Pool

by Zacks Equity Research

Surmodics' (SRDX) latest addition is expected to aid in performing more complex interventions which were earlier not possible.

Zacks Equity Research

HRC vs. SRDX: Which Stock Is the Better Value Option?

by Zacks Equity Research

HRC vs. SRDX: Which Stock Is the Better Value Option?

Zacks Equity Research

HRC vs. SRDX: Which Stock Is the Better Value Option?

by Zacks Equity Research

HRC vs. SRDX: Which Stock Is the Better Value Option?

Zacks Equity Research

Surmodics' (SRDX) Q3 Earnings, Revenues Fall Shy of Estimates

by Zacks Equity Research

Higher revenues from the IVD segment drives Surmodics' (SRDX) fiscal third-quarter top line.

Zacks Equity Research

SurModics (SRDX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

SurModics (SRDX) delivered earnings and revenue surprises of -54.55% and -0.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: SurModics (SRDX) Q3 Earnings Expected to Decline

by Zacks Equity Research

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

HRC vs. SRDX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

HRC vs. SRDX: Which Stock Is the Better Value Option?

Zacks Equity Research

Surmodics (SRDX) Boosts Portfolio With Vetex Medical Buyout

by Zacks Equity Research

Surmodics' (SRDX) buyout of Vetex Medical adds second FDA 510 (k) cleared device to its thrombectomy platform.

Zacks Equity Research

HRC vs. SRDX: Which Stock Is the Better Value Option?

by Zacks Equity Research

HRC vs. SRDX: Which Stock Is the Better Value Option?

Zacks Equity Research

EYE or SRDX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EYE vs. SRDX: Which Stock Is the Better Value Option?

Zacks Equity Research

Surmodics (SRDX) Q2 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Surmodics (SRDX) records higher revenues in both its core units in the fiscal second quarter.

Zacks Equity Research

SurModics (SRDX) Beats Q2 Earnings Estimates

by Zacks Equity Research

SurModics (SRDX) delivered earnings and revenue surprises of 3.33% and -0.07%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?